Plewig, G., Landthaler, M., Burgdorf, W.H.C., Hertl M., Ruzicka T. (2012). Braun-Falco´s Dermatologie, Venerologie und Allergologie, 6. Auflage, Berlin Heidelberg, Springer Verlag.

Dirschka, T., Hartwig, R., Oster-Schmidt, C. (2010). Klinikleitfaden Dermatologie, 3. Auflage, Urban & Fischer Verlag/Elsevier GmbH.

Altmeyer P.. Altmeyers Enzyklopädie https://www.enzyklopaedie-dermatologie.de letzter Zugriff am 05.06.2019.

Krutmann, J., Gilchrest, A. (2006).Photoaging of skin. Berlin Heidelberg, Springer.

Röck, K., Fischer J.W. (2011). Rolle der extrazellulären Matrix bei der extrinsischen Hautalterung. Der Hautarzt 62(8), 591-597.

Krutmann, J. (2011). How the sun ages our skin. The dermis as the driving force. Der Hautarzt 62(8), 588-590.

Albrecht, S. et al. (2018). Skin type differences in solar-simulated radiation-induced oxidative stress. British Journal of Dermatology 180(3), 597-603.

Robert, C.et al. (2015). Low to moderate doses of infrared A irradiation impair extracellular matrix homeostasis of the skin and contribute to skin photodamage. Skin Pharmacology and Physiology 28(4), 196-204.

Weihermann, A.C., et al. (2017). Elastin structure and its involvement in skin photoaging. International Journal of Cosmetic Science, 39, 241-247.

Battie, C., Verschoore M. (2012). Cutaneous solar ultraviolet exposure and clinical aspects of photodamage. Indian Journal of Dermatology, Venereology and Leprology, 78(7), 9-14.

Cole M.A. et al. (2018). Extracellular matrix regulation of fibroblast function: redefining our perspective on skin aging. Journal of Cell Communication and Signalling 12(1), 35-43.

https://www.tk.de/presse/themen/arzneimittel/haut/hautkrebs-immer-noch-toedlich-2061200. Pressemitteilung TK. Letzter Zugriff 23.06.2019

Brown, S., Pineda, C.M., Xin, T., Boucher, J., Suozzi, K.C., Park, S., et al. (2017). Correction of aberrant growth preserves tissue homeostasis. Nature 548(7667), 334–337.

Cleaver, J.E. (2000). Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. Journal of Dermatological Science 23(1), 1-11.

Didona, D., Paolino, G., Bottoni, U., Cantisani, C.(2018). Non Melanoma Skin Cancer Pathogenesis Overview. Biomedicines. 6(1). pii: E6.

Elmets, C.A., Athar, M. (2013). Milestones in Photocarcinogenesis. Journal of Investigative Dermatology. 133(E1), E13-E17.

de Gruijl, F.R., Tensen C.P. (2018). Pathogenesis of Skin Carcinomas and a Stem Cell as Focal Origin. Frontiers in Medicine 29(5): 165. doi: 10.3389/fmed.2018.00165. eCollection 2018.

De Gruijl, F.R. (1999). Skin cancer and solar UV radiation. European Journal of Cancer 35(14), 2003-2009.

Ichihashi, M., Ueda, M., Budiyanto, A., Bito, T., Oka, M., Fukunaga, M., Tsuru, K., Horikawa, T. (2003). UV-induced skin damage. Toxicology. 15 (189, 1-2), 21-39.

Hodis, E. et al. (2012).A landscape of driver mutations in melanoma. Cell 150(2), 251-263.

Martens, M.C., Seebode, C., Lehmann, J., Emmert, S.(2018). Photocarcinogenesis and Skin Cancer Prevention Strategies: An Update.Anticancer Research 38(2):1153-1158.

Mullenders, L.H.F. (2018). Solar UV damage to cellular DNA: from mechanisms to biological effects. Photocheical & Photobiological Sciences. 17(12):1842-1852.

Nishisgori, C.(2015). Current concept of photocarcinogenesis. Photochemical and Photobiological Sciences 14(9),1713-21.

Pollet, M. et al. (2018). The AHR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis. Cell Death and Differentiation. 25(10), 1823–1836.

Ratushny, V., Gober, M.D. , Hick, R., Ridky, T.W., Seykora, J.T. (2012). From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. Journal of Clinical Investigation 122(2), 464-472.

Sander, C.S., Hamm, F., Elsner, P., Thiele, J.J.(2003). Oxidative stress in malignant melanoma and non-melanoma skin cancer. British Journal ofDermatology 148(5), 913-922.

Vaccariello, M., Javaherian, A., Wang, Y., Fusenig, N.E., Garlick, J.A.(1999). Cell interactions control the fate of malignant keratinocytes in an organotypic model of early neoplasia. Journal of Investigative Dermatology 113(3), 384-391.

Altmeyer P.. Altmeyers Enzyklopädie https://www.enzyklopaedie-dermatologie.de. Letzter Zugriff am 28.07.2019.

Bundesamt für Strahlenschutz https://www.bfs.de/DE/themen/opt/uv/uv-index/einfuehrung/einfuehrung.html. Letzter Zugriff am 13.08.2019.

https://www.tk.de/presse/themen/arzneimittel/haut/hautkrebs-immer-noch-toedlich-2061200. Pressemitteilung TK. Letzter Zugriff 28.07.2019.

S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut (Version 1.0, Juni 2019, AWMF-Registriernummer: 032/022OL) https://www.leitlinienprogramm-onkologie.de/leitlinien/aktinische-keratose-und-plattenepithelkarzinom-der-haut/

S3-Leitlinie Prävention von Hautkrebs (Version 1.1. – April 2014, AWMF-Registernummer: 032/052OL). https://www.leitlinienprogramm-onkologie.de/leitlinien/hautkrebs-praevention/

S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms (Version 3.1. – Juli 2018, AWMF-Registernummer: 032/024OL). https://www.awmf.org/leitlinien/detail/ll/032-024OL.html

Didona, D. et al. (2018). Non Melanoma Skin Cancer Pathogenesis Overview. Biomedicines 6(1), 6.

Hübner, J., >Eisemann, N., Bunßen, A., Katalinic, A. (2018). Hautkerbsscreening in Deutschland: Bilanz nach zehn Jahren. Bundesgesundheitsblatt – Gesundheitsdorschung – Gesundheitsschutz, 61(12), 1536-1543.

Leiter, U., Eigentler, T., Garbe, C. (2014). Epidemiology of Skin Cancer. In: Sunlight, Vitamin and Cancer. New York, Springer Verlag.

Rudolph, C. et al. (2015). Inzidenztrends bei nicht‐melanozytärem Hautkrebs in Deutschland von 1998 bis 2010. Journal of the German Society of Dermatology, 13(8),788-798.

Wagener, C., Müller, O. (2010). Molekulare Onkologie, Entstehung, Progression, klinische Aspekte, 3. Auflage, Stuttgart, Thieme Verlag.

Robert Koch-Institut (Hrsg.), Zentrum für Krebsregisterdaten im Robert Koch-Institut (2016). Bericht zum Krebsgeschehen in Deutschland. Berlin. https://edoc.rki.de/bitstream/handle/176904/3264/28oaKVmif0wDk.pdf?sequence=1

Van Zijl, F., Krupitza, G., Mikulits, W.. (2011). Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research/Reviews in Mutation Research, 728(1-2), 23-34.

Augustin, M., Wilsmann-Theis, D., Körber, A., Kerscher, M., Itschert, G., Dippel, M., Staubach, P. (2018). Positionspapier: Diagnostik und Therapie der Xerosis cutis. Journal der Deutschen Dermatologischen Gesellschaft, 16(S4), 3-35.

Hornung, T., Bieber, T. (2018). Therapie der atopischen Dermatitis: Nach wie vor eine besondere Herausforderung. Deutsches Ärzteblatt 115, 20-21.

Kubo, A., Nagao, K., Amagai, M. (2012). Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. The Journal of Clinical Investigation. 122(2), 440-447.

Rerknimitr, P., Otsuka, A., Nakashima, C., Kabashima, K. (2017).The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflammation and Regeneration. 37: 14.

Riethmuller, C. et al. (2015). Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis.The Journal of Allergy and Clinical Immunology. 134(6), 1573-1580.e2.

Werfel, T., Schwerk, N., Hansen, G., Kapp, A. (2014). Diagnostik und Stufentherapie der Neurodermitis. Deutsches Ärzteblatt 111, 509-520.

Wollenberg, A. et al. (2018). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children:part I. Journal of the European Academy of Dermatology and Venerology 32, 657-682.

S2k-Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] (April 2008, letzte Überarbeitung 03/2015, AWMF-Registernummer: 013-027) https://www.awmf.org/uploads/tx_szleitlinien/013-027l_S2k_Neurodermitis_2016-06-verlaengert.pdf. Letzter Zugriff 24.09.2019.

https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_de.pdf letzter Zugriff 5.10.2019

Beck, L.A. et al. (2014). Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New England Journal of Medicine 371, 130-139.

Blauvelt, A. et al. (2017). Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389, 2287-2303.

Hamilton, J.D. et al. (2014). Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology 134, 1293- 1300.

Thaçi, D. et al. (2016). Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387, 40–52.

weitere Quellen: siehe Beitrag “Wieso Basispflege bei Neurodermitis wichtig ist”

Baranska, A. et al. (2018). Unveiling skin macrophage dynamics explains both tattoo persistence and strenuous removal. Journal of Experimental Medicine 215 (4), 1115-1133.

Bäumler W. (2016). Tattoos and Their Potential Health Consequences.
Deutsches Ärzteblatt International (2016) 113 (40), 663-664.

Kaur, RR., Kirby, W., Maibach, H. (2009). Cutaneous allergic reactions to tattoo ink. Journal of Cosmetic Dermatology 8 (4), 295-300.

Sepehri, M. et al. (2017). Tattoo Pigments Are Observed in the Kupffer Cells of the Liver Indicating Blood-Borne Distribution of Tattoo Ink. Dermatology 233, 86-93.

Serup, J. et al. (2015). Tattoo Complaints and Complications: Diagnosis and Clinical Spectrum. Current Problems in Dermatology 48, 48-60.

Torbeck, R., Bankowski, R., Henize, S., Saedi, N. (2016). Lasers in tattoo and pigmentation control: role of the PicoSure(®) laser system. Medical Devices: Evidence and Research (Auckl) 2(9), 62-67.

Ärzteblatt.de: https://www.aerzteblatt.de/nachrichten/sw/T%E4towieren?nid=95766. Letzter Zugriff am 29.11.2019.

S3-Leitlinie zur Therapie der Psoriasis vulgaris, Update 2017. Registernummer 013-001. https://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Therapie_Psoriasis-vulgaris_2017-12.pdf

Bai, F. et al. (2019). Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Journal of Immunology Research. 2019: 2546161.

Hawkes, J. E., et al. (2017). Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies. The Journal of allergy and clinical immunology. 140 (3): 645-653.

Rendon, A., Schaekel, K. (2019). Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences. 20(6): 1475.

https://www.aerzteblatt.de/archiv/62880/Psoriasis-neue-Erkenntnisse-zur-Pathogenese-und-Therapie

https://www.enzyklopaedie-dermatologie.de/dermatologie/psoriasis-3339 (letzter Zugriff am 16.5.20)

https://www.aerzteblatt.de/archiv/180688/Psoriasis-vulgaris-Die-Last-der-Begleiterkrankungen (letzter Zugriff am 01.05.20)

https://www.psoriasis-bund.de/fileadmin/images/broschueren/Patientenleitlinie_zur_Behandlung_der_Psoriasis_der_Haut.pdf (letzter Zugriff am 05.09.2020)

https://www.psoriasis.info/therapie/medikamente-biologika (letzter Zugriff am 05.09.2020)

https://www.karger.com/Article/FullText/481335https://www.abbvie-care.de/content/uploads/2018/10/abbvie-care-was-sind-biologika.pdf (letzter Zugriff am 05.09.2020)

https://www.enzyklopaedie-dermatologie.de/dermatologie/biologika-in-der-dermatologie-15190 (letzter Zugriff am 05.09.2020)